SCHEMBL3937008

SCHEMBL3937008

O=C(O)C=CC=C(c1ccc(OC2CCC2)cc1)c1ccc(C(F)(F)F)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP10 Q53GL7 1/20 0.49
EPHX2 P34913 4/20 0.47
TEAD1 P28347 1/20 0.46
ADRB2 P07550 1/20 0.44
LIPE Q05469 1/20 0.39
ACACB O00763 1/20 0.38
HRH3 Q9Y5N1 1/20 0.38
BCL2A1 Q16548 1/20 0.38
MMP2 P08253 1/20 0.37
MMP13 P45452 1/20 0.37
NR4A1 P22736 1/20 0.37
NR4A2 P43354 1/20 0.37
NR4A3 Q92570 1/20 0.37
CYP1A1 P04798 1/20 0.37
CYP1B1 Q16678 1/20 0.37
MAOB P27338 1/20 0.37
NPC1 O15118 1/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
RAB9A P51151 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3937004 1.00 PARP10 (0.49) PARP10EPHX2TEAD1ADRB2LIPE
SCHEMBL3948185 0.95 EPHX2 (0.51) PARP10EPHX2TEAD1ADRB2LIPE
SCHEMBL3948188 0.95 EPHX2 (0.51) PARP10EPHX2TEAD1ADRB2LIPE
SCHEMBL3946996 0.90 EPHX2 (0.44) PARP10EPHX2TEAD1ADRB2LIPE
SCHEMBL3946999 0.90 EPHX2 (0.44) PARP10EPHX2TEAD1ADRB2LIPE
SCHEMBL3946995 0.90 EPHX2 (0.44) PARP10EPHX2TEAD1ADRB2LIPE
SCHEMBL4025148 0.87 LMNA (0.51) EPHX2TEAD1ADRB2NR4A1NR4A2
SCHEMBL4025146 0.87 LMNA (0.51) EPHX2TEAD1ADRB2NR4A1NR4A2
SCHEMBL4025153 0.87 LMNA (0.51) EPHX2TEAD1ADRB2NR4A1NR4A2
SCHEMBL4205841 0.87 EPHX2 (0.41) PARP10EPHX2TEAD1ADRB2NR4A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090203667-A1 PENTADIENAMIDE DERIVATIVES KYOWA HAKKO KIRIN CO., LTD. (JP) 2009-08-13 US disclosed
EP-2050734-A1 PENTADIENAMIDE DERIVATIVE Kyowa Hakko Kirin Co., Ltd. (JP) 2009-04-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203667-A1 PENTADIENAMIDE DERIVATIVES PRMT1, REN, NGLY1 PARP10 1526/4885EPHX2 3390/4885TEAD1 4389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.